<SEC-DOCUMENT>0001193125-21-109799.txt : 20210408
<SEC-HEADER>0001193125-21-109799.hdr.sgml : 20210408
<ACCEPTANCE-DATETIME>20210408111059
ACCESSION NUMBER:		0001193125-21-109799
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210408
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210408
DATE AS OF CHANGE:		20210408

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Repare Therapeutics Inc.
		CENTRAL INDEX KEY:			0001808158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39335
		FILM NUMBER:		21814151

	BUSINESS ADDRESS:	
		STREET 1:		7210 FREDERICK-BANTING, SUITE 100
		CITY:			ST-LAURENT
		STATE:			A8
		ZIP:			H4S 2A1
		BUSINESS PHONE:		(857) 412-7018

	MAIL ADDRESS:	
		STREET 1:		7210 FREDERICK-BANTING, SUITE 100
		CITY:			ST-LAURENT
		STATE:			A8
		ZIP:			H4S 2A1
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d143708d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM
8-K</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section 13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): April 8, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Repare Therapeutics Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Qu&eacute;bec</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-39335</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>7210 Frederick-Banting, Suite 100</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">St-Laurent,</FONT> Qu&eacute;bec, Canada</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>H4S 2A1</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s Telephone Number, Including Area Code: (857)
<FONT STYLE="white-space:nowrap">412-7018</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or Former Address, if Changed Since Last Report.) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common shares, no par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>RPTX</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company &#9746; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act. &#9744; </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repare Therapeutics Inc., a corporation governed by the <I>Business Corporations Act</I> (Qu&eacute;bec) (the &#147;Company&#148;) will host a Virtual Investor
Day beginning at 10:30 a.m. Eastern Time on Thursday, April&nbsp;8, 2021, at which the Company will present on the progress of its proprietary drug discovery program, <FONT STYLE="white-space:nowrap">RP-6306.</FONT> The Company&#146;s <FONT
STYLE="white-space:nowrap">RP-6306</FONT> product candidate is a synthetic lethal inhibitor focused on tumors with genetic alterations characterized by cyclin E1 (&#147;CCNE1&#148;) amplification. The Company is posting a copy of the Virtual
Investor Day presentation to the &#147;Investors&#148; section of its website at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://ir.reparerx.com/events/event-details/virtual-investor-day-rp-6306-ccne-1-synthetic-lethal-inhibitor.
</FONT></FONT></FONT></FONT></FONT> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;8, 2021, the Company issued a press release announcing highlights of its Virtual Investor Day webcast, including the proposed clinical trial
design of the Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">RP-6306.</FONT> This trial is expected to enroll patients suffering from recurrent tumors characterized by CCNE1 amplification and other genomic alterations predicted to be
sensitive to <FONT STYLE="white-space:nowrap">RP-6306.</FONT> A copy of the release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibit. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d143708dex991.htm">Press release dated April&nbsp;8, 2021. </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>REPARE THERAPEUTICS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lloyd M. Segal</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lloyd M. Segal</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief
Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April&nbsp;8, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d143708dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g143708qtaa.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Repare Therapeutics to Highlight
Program Progress for <FONT STYLE="white-space:nowrap">RP-6306</FONT> at Today&#146;s Virtual Investor Day Event </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>-Company highlights
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> anti-tumor activity of <FONT STYLE="white-space:nowrap">RP-6306,</FONT> a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> selective, oral inhibitor
of PKMYT1, which is synthetic lethal with CCNE1 amplification and other genomic mutations- </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Initiation of Phase 1 clinical trial
enrollment for <FONT STYLE="white-space:nowrap">RP-6306</FONT> anticipated to begin during this quarter- </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>-Conference call and
webcast on Thursday, April&nbsp;8 at 10:30 a.m. ET will feature academic experts Carol Aghajanian, M.D. </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>and Timothy Yap, MBBS,
Ph.D., FRCP- </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cambridge, MA</B><B></B><B>&nbsp;&amp; Montreal, QC,</B><B></B><B>&nbsp;April</B><B></B><B>&nbsp;8, 2021 (BUSINESS WIRE)</B> &#151;
Repare Therapeutics Inc. (&#147;Repare&#148; or the &#147;Company&#148;) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel
therapeutics, will host a virtual Investor Day webcast today from 10:30 a.m. &#150; 12:00 p.m. ET, highlighting the progress of its proprietary <FONT STYLE="white-space:nowrap">RP-6306</FONT> program for tumors with genetic alterations characterized
by CCNE1 amplification. The Company expects to initiate a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">RP-6306</FONT> in the second quarter of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;At today&#146;s event, we will be reviewing the compelling <FONT STYLE="white-space:nowrap">pre-clinical</FONT> anti-tumor activity of <FONT
STYLE="white-space:nowrap">RP-6306,</FONT> our first- <FONT STYLE="white-space:nowrap">in-class,</FONT> selective, oral inhibitor of PKMYT1 to treat CCNE1-amplified, FBXW7-altered and other undisclosed PKMYT1 inhibitor-sensitive cancers. Our <I>in
vivo</I> and other <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data indicate that <FONT STYLE="white-space:nowrap">RP-6306</FONT> can selectively inhibit tumors with these specific alterations when used as a monotherapy and in combination
with other agents. We plan to initiate a Phase 1 clinical trial during this quarter, which is a quarter ahead of previously announced guidance,&#148; said Lloyd M. Segal, President and Chief Executive Officer of Repare. &#147;We look forward to
advancing our <FONT STYLE="white-space:nowrap">RP-6306</FONT> program into the clinic.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;There is a high unmet medical need for better
treatments for patients with homologous recombinant-proficient cancers. The incidence of such cancers is rising and represents a growing therapeutic challenge.&#148; said Maria Koehler, MD, PhD, Chief Medical Officer of Repare. &#147;Targeting DNA
damage repair using synthetic lethal strategies is a massive opportunity to build on the success of PARP inhibitors. The field is rapidly expanding beyond PARP inhibitors and has been accelerated by the discovery of novel targets enabled by cancer
genome sequencing and CRISPR technologies.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Highlights from the Virtual Investor Day </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Pre-Clinical</FONT> Data Findings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using its proprietary, CRISPR-based SNIPRx discovery platform, Repare has identified PKMYT1 as a strong hit in a CCNE1-overexpression synthetic lethal screen.
PKMYT1 is a kinase that phosphorylates CDK1, thereby holding the cyclin <FONT STYLE="white-space:nowrap">B-CDK1</FONT> complex in an inactive state until the cell is ready to enter mitosis. The Company&#146;s product candidate <FONT
STYLE="white-space:nowrap">RP-6306</FONT> is being developed as a highly potent and selective PKMYT1 inhibitor that preferentially kills tumor cells overexpressing CCNE1 and has shown to inhibit the growth of a broad range of CCNE1-amplified tumors
in xenograft/PDX preclinical models, both as a single agent and in combination therapy settings. <FONT STYLE="white-space:nowrap">RP-6306</FONT> has been observed to have a favorable <FONT STYLE="white-space:nowrap">pre-clinical</FONT> PK profile as
well as low potential for drug-drug interactions. Application of Repare&#146;s STEP<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> genome-wide chemical screen has identified other gene alterations beyond CCNE1 amplification that are uniquely
targetable by <FONT STYLE="white-space:nowrap">RP-6306,</FONT> including tumors that have loss of FBXW7 function, a cell-cycle regulator that has been implicated as a key genetic driver in a broad range of cancers, and represent further areas of
unmet medical need. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">RP-6306</FONT> Phase 1 Clinical Trial Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repare plans to initiate enrollment of a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">RP-6306</FONT> during this quarter. Study objectives
include assessment of safety, tolerability, dose and schedule (including the recommended Phase 2 dose). Subject to completion and review of the Phase 1 clinical trial, the Company expects to advance <FONT STYLE="white-space:nowrap">RP-6306,</FONT>
both as monotherapy and in combination with chemotherapies and other agents, into <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies in 2022 targeting a variety of patient populations, including
those with tumors with CCNE1 amplification, FBXW7 loss or other undisclosed alterations identified through its proprietary STEP<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> screen. Prospective enrichment of study patient populations will be
guided by its ongoing efforts to develop patient selection biomarkers covering both target engagement and functional (DNA damage) readouts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Virtual
Investor Day Agenda </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10:30 a.m. &#150; 10:35 a.m. ET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Introduction </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lloyd Segal, President and Chief Executive
Officer, Repare Therapeutics </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10:35 a.m. &#150; 10:50 a.m. ET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Targeting DNA Damage Repair in the Clinic </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Timothy Yap, MBBS,
Ph.D., FRCP </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Medical Director, Institute for Applied Cancer Science, and Associate Professor, Department of Investigational Cancer Therapeutics,
Division of Cancer Medicine at MD Anderson Cancer Center </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10:50 a.m. &#150; 11:05 a.m. ET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genomic Classifications of Endometrial&nbsp;&amp; Ovarian Cancers is Standard of Care </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unmet Need: Therapies Targeting CCNE1 &amp; FBXW7 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Carol
Aghajanian, M.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chief of Gynecologic Medical Oncology Service and Professor of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering
Cancer Center </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11:05 a.m. &#150; 11:35 a.m. ET </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Target Discovery&nbsp;&amp; Biology of <FONT STYLE="white-space:nowrap">RP-6306</FONT> &amp; STEP Characterization Table </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Michael Zinda, Ph.D., Executive Vice President, Chief Scientific Officer, Repare Therapeutics </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11:35 a.m. &#150; 11:45 a.m. ET </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Translational&nbsp;&amp;
Clinical Plan for <FONT STYLE="white-space:nowrap">RP-6306</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Maria Koehler, M.D., Ph.D., Executive Vice President, Chief Medical Officer, Repare
Therapeutics </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11:45 a.m. &#150; 12:00 p.m. ET </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conclusion&nbsp;&amp; Q&amp;A Session </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call and
Webcast </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To access the event virtual event, please dial&nbsp;(833) <FONT STYLE="white-space:nowrap">638-9655</FONT> (U.S. and Canada) or (602) <FONT
STYLE="white-space:nowrap">585-9856</FONT> (international) at least 10&nbsp;minutes prior to the start time and refer to conference ID 1093819. A live video webcast will be available in the Investor section of the Company&#146;s website at <U><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://ir.reparerx.com/news-and-events/events</FONT></FONT></U>. A webcast replay will also be available on the corporate website at the conclusion of the call. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">RP-6306</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">RP-6306,</FONT> the result of Repare&#146;s proprietary drug discovery program, is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> selective, oral inhibitor of PKMYT1 to
treat CCNE1-amplified, FBXW7-altered and other PKMYT1 inhibitor-sensitive cancers that typically do not respond well to platinum or PARP inhibitor treatment. Through Repare&#146;s SNIPRx screen campaign for targets that are SL with CCNE1
amplification, the Company identified and validated this novel SL gene that has the characteristics of a therapeutic target. Subsequently, the Company developed novel and selective inhibitors against PKMYT1, which repeatedly demonstrated compelling
anti-tumor activity, and announced the advancement of a clinical candidate for this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> program. Repare anticipates initiating a Phase 1 clinical trial of <FONT
STYLE="white-space:nowrap">RP-6306</FONT> during the quarter ending June&nbsp;30, 2021. This trial is expected to enroll patients suffering from recurrent tumors characterized by CCNE1 amplification or other genomic alterations predicted to be
sensitive to <FONT STYLE="white-space:nowrap">RP-6306.</FONT> The primary objective of the trial is to assess preliminary safety in patients and to establish the RP2D and schedule for <FONT STYLE="white-space:nowrap">RP-6306</FONT> for further
studies as a monotherapy. Dependent on Phase 1 result, an additional trial is planned to evaluate the combination of <FONT STYLE="white-space:nowrap">RP-6306</FONT> with approved anti-cancer agents, including chemotherapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Repare Therapeutics, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repare Therapeutics is a
leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company&#146;s pipeline includes its lead product
candidate <FONT STYLE="white-space:nowrap">RP-3500,</FONT> a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> ATR inhibitor currently in Phase 1/2 clinical development, as well as RP- 6306, a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> selective, oral inhibitor of PKMYT1 to treat CCNE1-amplified, FBXW7-altered and other PKMYT1 inhibitor-sensitive cancers, and a Pol<FONT
STYLE="FONT-FAMILY:SYMBOL">&#113;</FONT>&cedil; inhibitor program. For more information, please visit reparerx.com. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SNIPRx<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a registered trademark of Repare
Therapeutics Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
press release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are &#147;forward-looking
statements. These statements may be identified by words such as &#147;aims,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;forecasts,&#148; &#147;goal,&#148;
&#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;seeks,&#148; &#147;will&#148; and variations of these words or similar expressions that are intended to identify forward-looking statements,
although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, the clinical development of <FONT STYLE="white-space:nowrap">RP-6306</FONT> including the initiation,
timing, design and results of the Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">RP-6306;</FONT> the efficacy of <FONT STYLE="white-space:nowrap">RP-6306</FONT> as a monotherapy or in combination with other therapies; and the
Company&#146;s ability to identify and develop additional product candidates using its SNIPRx platform. These forward-looking statements are based on the Company&#146;s expectations and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties that could cause the Company&#146;s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many
factors may cause differences between current expectations and actual results, including the impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s business, clinical trials and financial position, unexpected
safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the
uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause the Company&#146;s actual results to differ from those expressed or implied in the forward-looking statements in
this press release are identified in the section titled &#147;Risk Factors&#148; in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended&nbsp;December 31, 2020&nbsp;filed with the&nbsp;Securities
and Exchange Commission&nbsp;(&#147;SEC&#148;) on&nbsp;March 4, 2021. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed
circumstances or otherwise, except as otherwise required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repare Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steve Forte </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repare Therapeutics Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>info@reparerx.com </U></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Argot Partners </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>repare@argotpartners.com </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-600-1902</FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Rosen </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Argot Partners </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>david.rosen@argotpartners.com </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-600-1902</FONT></FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g143708qtaa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g143708qtaa.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M=%U)-(B@2627R9OLR)IMFLQ1HG0"-G88S1L&Q0_95T#P?^UK^UKI;?M(^/\
M6_[=\=>)HM><1Z/8R6GQ UZT<7\GA34]1CN[=/#5G>V5B+*!;33YD9-MI";1
MC"]'Z!^A^K'_  6UCCA^"_P6BB1(HHOB5J$<<<:A$CC3PI?*B(B@!$50
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M*ZO)YIKU&464D%[:K&J3,0T<F44$%C8-CQ[XVZ#=Z+^T7XM\6R:-I>NVVO\
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#(__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
